Skip to main content
. 2018;64(1):9–14. doi: 10.5387/fms.2018-02

Fig. 2.

Fig. 2.

Drugs approved in Japan or candidate targeted drugs against driver gene aberrations in lung adenocarcinoma (LADC). Driver gene aberrations in EGFR, KRAS, HER2, and BRAF; driver fusions involving ALK, RET, and ROS1; and skipping of MET exon 14 were examined in 319 LADC patients who had undergone surgical resection at the National Cancer Center Hospital13)